cleared CellSearch (Janssen Diagnostics) technology, a semi-automated platform 27 that uses immunomagnetic enrichment of CTCs based on expression of epithelial 28 cell adhesion molecule (EpCAM) [3] . Using this platform, CTCs were found in 36% 29 of patients with pancreatic NETs and 53% of those with midgut NETs. The presence 30
of CTCs is associated with a worse overall survival, and early changes in CTC 31 number following treatment in NET patients are also prognostic [4, 5] . CTCs may 32 also be considered as 'liquid biopsies', offering the opportunity to interrogate the 33 molecular characteristics of the tumour. For such an approach to be broadly 34 applicable, alternative technologies are required to increase number of CTCs 35 isolated and the proportion of patients in which they can be detected. 36
37
The CellCollector (GILUPI GmbH) is a novel medical device consisting of a 160mm 38 sterile steel wire of which the terminal 20mm is coated with anti-EpCAM antibodies 39 covalently coupled to a gold and hydrogel layer. The CellCollector is inserted into a 40 peripheral vein enabling the circulating blood volume to be sampled. The wire is 41 Czech Republic). Finally, the wire was incubated in the nuclear stain, Hoesch 33342 61 (Sigma), (concentration 1ug/ml). The wire was examined in a bespoke holder 62 allowing inspection in four planes using an Axio Imager microscope with digital 63 camera and AxioVision software. 64 negative for CD45, 4. Nuclear stain distinct from the cytokeratin or EpCAM staining. 68
Examples of positively identified CTCs are shown in Figure 1B . The number of CTCs 69 was enumerated by two independent operators who were blind to the patient's (Table 1) . Therefore, CTCs were 82 detected in greater numbers and a greater proportion of patients with the 83 CellCollector ( Figure 1D ). The CellCollector identified CTCs in all midgut NETs, and 84 12/13 PNETS. 85
86
We explored the prognostic relevance of CTC count according to CellCollector. With 87 a median follow-up period of 13 months, overall survival data was insufficiently 88 mature so we examined progression free survival (PFS) as a surrogate. Overall, 14 89 patients had progression by RECIST criteria and applying a cut-off of 7 CTCs, there 90 was a significant difference in PFS (Cox Hazard Ratio 3.4, P<0.05). Using the same 91 threshold in the Kaplan Meier survival analyses ( Figure 1E ), median PFS was 11 92 months for patients with ≥7CTCs but not reached for those with <7 (Log Rank the CellSearch has been extensively validated and remains a robust method for 98 prognostication whilst the CellCollector offers the potential to make molecular 99 analysis of CTCs more widely applicable. Indeed, a recent study in lung cancer 100 demonstrated both KRAS and EGFR mutations known to be present in the primary 101 tumour, in CTCs derived from the CellCollector using chip-based digital PCR [8] . 102
Other strategies to increase the volume of blood sampled for CTCs include the use 103 of leukapheresis [9] . However, the leukapheresis product has a very high rate of 104 contaminating leukocytes and requires downstream enrichment methods to isolate 105
CTCs. Compared with CellCollector, leukapheresis is also more time-consuming, 106 expensive and onerous for patients [10] . 107
The CellCollector, like CellSearch, is limited by the dependence on EpCAM as a 108 selection marker for CTCs, and a biologically important component of EpCAM 109 negative CTCs will not be sampled by either technology. Marker agnostic devices 110 based on size exclusion or biophysical properties rather than antigen expression, 111 offer an alternative method of CTC isolation but remain limited by the small volume 112 of blood that can be sampled. 113
In summary, the CellCollector appears to be a promising innovation that may help 114 enhance our understanding of CTC biology and the mechanism of metastasis. 115 
